Last reviewed · How we verify
CJ-30060
At a glance
| Generic name | CJ-30060 |
|---|---|
| Sponsor | HK inno.N Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of CJ-30060 in Healthy Volunteers (PHASE1)
- Bioequivalence Study of CJ-30060 in Healthy Male Volunteers (PHASE1)
- Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia (PHASE3)
- Pharmacokinetics Study of CJ-30060 After Single Dose Administration in Health Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CJ-30060 CI brief — competitive landscape report
- CJ-30060 updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI